ភាគហ៊ុនរបស់ Dexcom ធ្លាក់ចុះដោយសារពាក្យចចាមអារ៉ាមថា វាអាចទទួលបាន Insulet នៅក្នុងកិច្ចព្រមព្រៀង 'ផ្លាស់ប្តូរ'

Dexcom stock tumbled Tuesday on rumors that it’s in talks to acquire insulin pump-maker អាំងស៊ុយលីត (ផ។ ឌី។ ឌី).

X

The potential deal, first reported by Bloomberg, would create a behemoth in ការគ្រប់គ្រងជំងឺទឹកនោមផ្អែម. ឌិកខម (DXCM) makes continuous glucose monitors, or CGMs, that keep tabs on patients’ blood sugar. Insulin pumps can be connected to CGMs to create a more seamless process.

“Such a potential deal, if it were to happen, would likely be transformative and impactful to the diabetes technology landscape,” BTIG analyst Marie Thibault said in a note to clients.

នៅ​លើ ផ្សារភាគហ៊ុនថ្ងៃនេះ, Dexcom stock toppled 11.1% to 288.13. Insulet stock, on the other hand, surged 7.4% to 217.83.

Dexcom Stock Has Tumbled This Year

The rumored deal’s timing is odd, however, Thibault said. Dexcom stock hit a record high in November, but has dropped off precipitously since then. Shares have fallen 46% this year as of Tuesday’s close. At the same time, Insulet shares have skidded 18%.

“The timing appears less favorable if accomplished at least in part via stock,” she said. Further, it would be a departure from Dexcom’s focus in securing patients with less severe diabetes that doesn’t require insulin treatment.

Thibault added it also could limit cooperation between diabetes technology firms. Dexcom’s CGMs can be integrated with ការថែទាំជំងឺទឹកនោមផ្អែម Tandemរបស់ (TNDM) insulin pumps. Insulet is reportedly working to integrate its insulin pump with មន្ទីរពិសោធន៍អាបុត'(ABT) glucose monitor.

“It is not clear whether that kind of collaboration could continue with a potential merger,” she said.

Still, Thibault kept her buy ratings on Dexcom stock and Insulet stock.

Major Players With Strong Growth

Representatives of the two companies declined to comment to Investor’s Business Daily.

Last year, Insulet’s sales grew 22% to $1.1 billion as Dexcom revenue climbed 27% to $2.45 billion. The deal would unite “two fast-growing major players entering new product cycles” with growth projected above 20% over the next few years, Thibault said.

Still, shares of both companies trade below their key moving averages, according to MarketSmith.com. Dexcom stock and Insulet stock fell below their បន្ទាត់ 200 ថ្ងៃ។ ខែមុន។

តាម Allison Gatlin នៅលើ Twitter នៅ @IBD_AGatlin.

អ្នកអាចចូលចិត្តបានផងដែរ៖

Pfizer’s Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way

The Big Covid Bet On China: Do Pfizer, Moderna Shots Stand A Chance?

តើធ្វើដូចម្តេចដើម្បីស្រាវជ្រាវភាគហ៊ុនកំណើន: ហេតុអ្វីបានជាឧបករណ៍ IBD នេះងាយស្រួលស្វែងរកការស្វែងរកភាគហ៊ុនកំពូល

ភាគហ៊ុនរីកចម្រើនល្អបំផុតដើម្បីទិញនិងមើល: សូមមើលការធ្វើបច្ចុប្បន្នភាពទៅបញ្ជីភាគហ៊ុនអេអាយឌីឌី

ទទួលបានការទិញនិងលក់ការដាស់តឿនឱ្យបានទាន់ពេលវេលាជាមួយតារាងពិន្ទុ IBD